Breaking News
Get 40% Off 0
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks
Close

ACADIA Pharmaceuticals Inc (ACAD)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow ACADIA's earnings

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
16.31 -0.28    -1.69%
16:00:04 - Closed. Currency in USD ( Disclaimer )
After Hours
16.35
+0.04
+0.25%
17:09:56 - Real-time Data
Type:  Equity
Market:  United States
  • Volume: 1,573,763
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 16.16 - 16.51
ACADIA 16.31 -0.28 -1.69%

NASDAQ:ACAD Financials

 
A brief overview of the NASDAQ:ACAD financials. This summary provides an overview of the most significant critical numbers from each of its financial reports, including the income statement, balance sheet, and cash flow statement. Additionally, it features several financial ratios that provide insight into the company's financial health. Users can select to view data from four periods of either annual or quarterly information, allowing them to track financial performance of ACADIA over time.

ACADIA Pharmaceuticals Inc. reported earnings results for the fourth quarter ended December 31, 2023. For the fourth quarter, the company reported revenue was USD 231.04 million compared to USD 136.49 million a year ago. Net income was USD 45.8 million compared to net loss of USD 41.73 million a year ago. Basic earnings per share from continuing operations was USD 0.28 compared to basic loss per share from continuing operations of USD 0.26 a year ago. Diluted earnings per share from continuing operations was USD 0.28 compared to diluted loss per share from continuing operations of USD 0.26 a year ago.

AnnualQuarterly  
InvestingPro Advanced Financial Summary
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

ACAD Income Statement

Gross margin TTM 45.86%
Operating margin TTM -10.1%
Net Profit margin TTM -8.44%
Return on Investment TTM -9.56%
 Total Revenue  Net Income
Period Ending: Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023
Total Revenue 231.04 211.7 165.24 118.46
Gross Profit 146.41 40.11 99 47.65
Operating Income 34.94 -57.78 3.04 -53.58
Net Income 45.8 -65.18 1.11 -43.02

ACAD Balance Sheet

Quick Ratio MRQ 2.11
Current Ratio MRQ 2.42
LT Debt to Equity MRQ -
Total Debt to Equity MRQ 13.25%
 Total Assets  Total Liabilities
Period Ending: Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023
Total Assets 748.96 632.54 642.77 655.3
Total Liabilities 317.2 270.37 246.98 281.05
Total Equity 431.76 362.17 395.79 374.26

ACAD Cash Flow Statement

Cash Flow/Share TTM 0.1
Revenue/Share TTM 4.42
Operating Cash Flow  33.59%
 Cash  Net Change in Cash
Period Ending: Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023
Period Length: 0 Months 0 Months 0 Months 0 Months
Cash From Operating Activities 85.39 -58.96 8.2 -17.93
Cash From Investing Activities -0.347 34.11 -194.28 192.52
Cash From Financing Activities 5.43 12.75 5.48 1.47
Net Change in Cash 90.46 -12.1 -180.6 176.05
* In Millions of USD (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

ACAD Comments

Write your thoughts about ACADIA Pharmaceuticals Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Cyrus Cyrus
Cyrus Cyrus Jun 23, 2022 10:17AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Mashallaha
Chijioke Nweke
Chijioke Nweke Aug 20, 2021 3:09AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
what is going on
Nitesh Chaudhari
Nitesh Chaudhari Jun 25, 2021 1:14PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Thuyii78857ujuuoukho0ojmBnmnmnBjjkjkBnjkh
St onks
St onks Jun 10, 2021 1:22PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
eh il wait til we trading above bollinger band to short, much safer
St onks
St onks Jun 10, 2021 1:22PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
woops wrong board
Rod All
Rod All May 30, 2021 9:25PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
slow ride to the moon but worth the wait
Rod All
Rod All May 23, 2021 9:03PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
going to the moon
Davis Davis
Davis Davis May 18, 2021 10:41AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
get back to 50 please
St onks
St onks May 10, 2021 3:27PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
4197 close imo
joninge kvamme
joninge kvamme Mar 16, 2021 1:29PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
A italian journalist predict a new clinical trail for the sustrate. This will take time i suppose.
joninge kvamme
joninge kvamme Mar 15, 2021 4:01PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Somebody knows something.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email